🇺🇸 Basal bolus insulin in United States

16 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Diabetic Ketoacidosis — 3 reports (18.75%)
  2. Blood Triglycerides Increased — 2 reports (12.5%)
  3. Caesarean Section — 2 reports (12.5%)
  4. Hyperglycaemia — 2 reports (12.5%)
  5. Off Label Use — 2 reports (12.5%)
  6. Blood Creatinine Increased — 1 report (6.25%)
  7. Drug Ineffective — 1 report (6.25%)
  8. Drug Interaction — 1 report (6.25%)
  9. Drug Level Increased — 1 report (6.25%)
  10. Exposure During Pregnancy — 1 report (6.25%)

Source database →

Basal bolus insulin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Basal bolus insulin approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Basal bolus insulin in United States?

Emory University is the originator. The local marketing authorisation holder may differ — check the official source linked above.